Publications by authors named "Hamdy Azim"

Claim this Profile
H
Homologous Recombination Deficiency Testing in Women With Ovarian Cancer: An Egyptian Multicentre Study.
Kyrillus S Shohdy, Loay Kassem, Boules Gabriel, Emad Barsoum, Tamer Elnahas, Hamdy A Azim

BJOG· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
Hamdy A Azim, Hagar Elghazawy, Kyrillus S Shohdy, Shaimaa Lasheen, Mahmoud Elghazawy

JCO Precis Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Social Determinants Associated With the Advanced-Stage Diagnosis of Breast Cancer.
Madonna A Fekry, Loay Kassem, Justin C Yang, Hamdy A Azim

JCO Glob Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2- breast cancer receiving neoadjuvant chemotherapy.
Hagar Elghazawy, Mahmoud Elghazawy, Hamdy A Azim, Mariam B Abouelkhair, Sara Hossam

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial.
Hamdy A Azim, Mariam A Saleh, Passant Essam Eldin, Ahmed A M Abdelhafeez, Mohamed Hassan

J Chemother· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
Hesham Elghazaly, Hamdy A Azim, Hope S Rugo, David Cameron, Sandra M Swain

Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, Yesim Eralp, Yoon Sim Yap

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer.
Hamdy A Azim, Samah A Loutfy, Hatem A Azim, Nermin S Kamal, Nasra F Abdel Fattah

Oncol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort.
Rasha Aboelhassan, Mohamed Emam Sobeih, Mohamed Alm El-Din, Ramy R Ghali, Ibtessam Saad El-Din, Hamdy A Azim

Ther Adv Med Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma.
Ashraf Omar, Ahmed Kaseb, Tamer Elbaz, Mohamed El-Kassas, Amr El Fouly, Hamdy Azim

J Hepatocell Carcinoma· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis.
Hamdy A Azim, Hagar Elghazawy, Ramy M Ghazy, Ahmed H Abdelaziz, Marwa Abdelsalam

JCO Glob Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Hamdy A Azim, Kyrillus S Shohdy, Hagar Elghazawy, Monica M Salib, Doaa Almeldin

Biomarkers· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
Joseph Gligorov, Xavier Pivot, Beyhan Ataseven, Michelino De Laurentiis, Kyung Hae Jung, Hamdy Abdel Azim

Breast· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Michelino De Laurentiis, Simona Borstnar, Mario Campone, Ellen Warner, Javier Salvador Bofill, Hamdy A Azim

Breast Cancer Res Treat· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Michelino De Laurentiis, Simona Borstnar, Mario Campone, Ellen Warner, Javier Salvador Bofill, Hamdy A Azim

Breast Cancer Res Treat· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
Hesham Elghazaly, Hope S Rugo, Hamdy A Azim, Sandra M Swain, Banu Arun

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating PARP inhibitors into the management of breast cancer: where are we?
Hamdy A Azim, Loay Kassem, Hatem Azim

Chin Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis.
Hamdy A Azim, Kyrillus S Shohdy, David F Kaldas, Loay Kassem, Hatem A Azim

Curr Probl Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the benefits and challenges of first-line cyclin-dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women.
Hamdy A Azim, Shaheenah Dawood, Nagi El-Saghir, Loay Kassem, Hatem A Azim

Breast J· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020.
Hamdy A Azim, Marwan Ghosn, Karima Oualla, Loay Kassem

Breast J· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OSSMAR: An Observational Study to Describe the Use of Sunitinib in Real-Life Practice for the Treatment of Metastatic Renal Cell Carcinoma.
Marwan Ghosn, Roland Eid, Emad Hamada, Hamdy Abdel Azim, Jamal Zekri

J Glob Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin.
Hamdy Abdel Azim, Loay Kassem, Kyrillus Samaan Shohdy, Boules Eshaak, Shady Elia Anis

J Breast Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study).
Hamdy A Azim, Ashraf Omar, Hesham Atef, Heba Zawahry, Mohamed K Shaker

J Hepatocell Carcinoma· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
Kyung Hae Jung, Beyhan Ataseven, Mark Verrill, Xavier Pivot, Michelino De Laurentiis, Hamdy A Azim

Oncologist· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of HER2-positive early breast cancer: How to best balance efficacy and toxicity?
Hamdy A Azim, Shaimaa Lasheen, Loay Kassem

Breast J· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis